The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in District of New Jersey on behalf of investors who purchased Sinovac Biotech Ltd. (NASDAQ : SVA) securities between April 30, 2013 and May 16, 2017.
According to the complaint, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendant Weidong Yin, Sinovac’s Chairman and CEO, bribed a member of the Chinese Food and Drug Administration to assist Sinovac’s vaccine clinical trial and approval; (2) Yin's conduct would subject Sinovac to heightened regulatory scrutiny; and (3) subsequently, Sinovac’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Sinovac Biotech Ltd. you have until September 1, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.